April 14, 2021
Business News

Spectrum Pharmaceuticals Presents Twice Daily Dosing Data for Poziotinib at the ESMO TAT Virtual Congress 2021


HENDERSON, Nev.–()–Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biopharmaceutical company focused on novel and targeted oncology therapies, today presented results from Cohort 3 and initial twice daily (BID) dosing safety and efficacy data for poziotinib from Cohort 5 of the ZENITH20 clinical trial. These preliminary data demonstrate improved tolerability with BID dosing, reduced dose interruption compared to once daily (QD) dosing, and a reduction in treatment emergent Grade 3 or higher adverse events. The preliminary data also suggest improved anti-tumor activity with 8mg BID dosing. The presentation is part of the European Society for Medical Oncology Targeted Anticancer Therapies (ESMO TAT) Virtual Congress…



Click here to view the original article.

Related Posts

You might also like ...

Africa’s Best Corporate-Startup Collaboration Accelerator, Startupbootcamp AfriTech, Now Open for Applications from the Most Disruptive Startups
Minnesota Department of Transportation Leverages Iteris’ ClearMobility Cloud for Improved Statewide Mobility
Bundesgerichtshof entscheidet zu Gunsten von Solvay im Patentstreit mit Neo